Bicycle Therapeutics Scheduled, Nasdaq: BCYC

Phase 1 biotech developing novel oncology medicines based on bicyclic peptides.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a clinical-stage biopharmaceutical company developing a novel class of medicines, which we refer to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycles are a unique therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic, or PK, properties of a small molecule. Bicycles are excreted by the kidney rather than the liver and have shown no signs of immunogenicity to date, which we believe together support a favorable toxicological profile.
more less
IPO News for Bicycle Therapeutics
more
IPO Data
IPO File Date 04/26/2019
Offer Price
Price Range $14.00 - $16.00
Offer Shares (mm) 4.3
Deal Size ($mm) $65
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $14.00 - $16.00
Offer Shares (mm) 4.3
Deal Size ($mm) $65
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Cambridge, United Kingdom
Founded 2009
Employees 61
Website www.bicycletherapeutics.com